Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 79 clinical trials
Featured trial
DECLARE -Dapagliflozin Effect on CardiovascuLAR Events - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients with Type 2 Diabetes

DECLARE -Dapagliflozin Effect on CardiovascuLAR Events - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of

  • 170 views
  • 25 Mar, 2021
  • 1 location
Featured trial
Clinical Protocol MB102230

Clinical Protocol MB102230

  • 260 views
  • 25 Mar, 2021
  • 1 location
Dapagliflozin and Hepatic Glucose Metabolism

the aim of this study is to examine the role of autonomic nervous system in the increase in hepatic glucose production in response to glucosuria caused by inhibition of renal glucose uptake

Accepts healthy volunteers
  • 0 views
  • 23 Jul, 2022
  • 1 location
Dapagliflozin (DAPA) Effects in HFpEF

The purpose of this study is to determine whether treatment with Dapagliflozin (DAPA) for 6 months will improve pulmonary capillary wedge pressure (PCWP) during exercise in heart failure

  • 0 views
  • 10 Apr, 2022
  • 1 location
Efficacy of Dapagliflozin in Diabetes Associated Peripheral Neuropathy (DINE)

Diabetic peripheral neuropathy(DPN) is a length dependent axonal neuropathy that affects at least 50% of patients with diabetes mellitus. DPN is often asymptomatic during the early stages of diabetes ,however, once symptoms and overt deficits have developed, it cannot be reversed. Early diagnosis of neuropathy is important because early diagnosis …

  • 0 views
  • 15 Jun, 2022
  • 1 location
Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure

This study will examine whether and how the FDA-approved drug dapagliflozin (Dapa) improves submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in

  • 0 views
  • 04 Nov, 2021
  • 1 location
DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk (DAPA-SWEET)

This study aims to elucidate the impact of SGLT2 inhibition on peripheral vascular function, renal function, fluid volume, neurohormonal activation and inflammatory/fibrotic pathways in patients with T2D at high cardiovascular risk and non-T2D patients.

hba1c
ace inhibitor
type 1 diabetes mellitus
heart disease
systolic blood pressure
  • 0 views
  • 25 Feb, 2022
Effect of Dapagliflozin in Patients With Acute Heart Failure (DAPA-RESPONSE-AHF)

Dapagliflozin, a sodium-glucose cotransporter-2 inhibitor (SGLT2i), increases natriuresis alone and synergistically when combined with loop diuretics in patients with AHF without increasing

  • 0 views
  • 19 Jun, 2022
  • 1 location
A Pharmacokinetic Study of SID1903 (FDC of Dapagliflozin and Sitagliptin) in Healthy Adult Volunteers

This study is to compare and evaluate the safety and pharmacokinetic characteristics (PK) after administration of SID1903 and SID1903-R1/SID1903-R2 in healthy adult volunteers.

Accepts healthy volunteers
  • 0 views
  • 25 Jul, 2022
  • 1 location
A Research Study Investigating How Semaglutide and Dapagliflozin Act in Your Body When Dosed in One Tablet

This study will test how the active substances semaglutide and dapagliflozin act in the body (in terms of their levels in the blood), when they are taken in the form of a combination preparation

Accepts healthy volunteers
  • 0 views
  • 29 Jul, 2022
  • 1 location